Table 3.

Serious adverse events (SAE) occurring in 6 patients under daptomycin-based antimicrobial therapy

Patient	Dose (mg/kg/d)	Additional antibiotic	SAE	SAE onset (days)	Cmin at SAE onset (mg/L)	Daptomycin withdrawal	Companion drug withdrawal
1	8,8	Rifampicin*	Neutropenia	73	NA	Yes	Yes
2	7,1	Rifampicin	Hypereosinophilia	92	NA	Yes	No
3	8,4	Rifampicin	Eosinophilic pneumonia, rhabdomyolysis	10	134	Yes	Yes
4	8,7	Pristinamycin	PICC thrombosis	12	NA	Yes	No
5	8,7	None	Eosinophilic pneumonia	23	38	Yes	NA
6	7,8	Linezolid	Acute renal failure	8	NA	Yes	Yes

In bold: SAE directly attributed to daptomycin

NA Not available, PICC Peripherally inserted central catheter, SAE Serious adverse event

*Rifampicin can induce both neutropenia and eosinophilia